** Shares of drug developer Eton Pharmaceuticals ETON.O fall ~3% to $12.58
** ETON says it has out-licensed the non-U.S. commercial rights for its rare disease drug, Increlex, to Spain's Esteve Pharmaceuticals
** Esteve will pay Eton 4 million euros ($4.32 million) upfront for the licensing rights lasting up to ten years
** ETON will still make the product and sell it to Esteve at a fixed price
** Esteve also receives an option to permanently acquire the international rights in the future for up to 6 million euros
** Increlex is used to treat growth failure in children and adolescents with severe primary insulin-like growth factor-1 deficiency
** Including session move, ETON fell 2.6% YTD
($1 = 0.9267 euros)
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。